The financing round added new investors including funds and accounts managed by BlackRock, RA Capital Management, and two undisclosed healthcare-focused funds.
Existing investors including founding investor Longwood Fund, 6 Dimensions Capital, Bessemer Venture Partners, GV, Novartis Venture Fund and Pitango HealthTech also participated in the round.
Proceeds from this financing will be used to advance TScan's TCR-T cell therapy pipeline for solid and liquid tumors into the clinic.
TScan is advancing a multi-TCR T cell therapy program for solid tumors, with plans to nominate an initial set of three target candidates in 2021 and IND submissions to follow in 2022.
The company also signed a strategic partnership with Novartis in 2020 for the discovery of novel oncology targets in a select solid tumor indication.
TScan expects to complete IND-enabling studies for two of its liquid tumor programs, TSC-100 and TSC-101, and submit INDs for both programs with the US Food and Drug Administration in the second half of 2021.
The company is also exploring use of its novel target discovery technology for both infectious and autoimmune diseases.
TScan discovers and develops transformative T cell therapies (TCR-T) to treat solid tumors and hematologic malignancies, as well as other serious diseases.
Our proprietary, high-throughput platform identifies novel, clinically-derived, shared T cell antigens and all off-target TCR interactions. TScan is applying this platform to the development of highly efficacious TCR-T cell therapies with minimal off-target effects.
Lead programs TSC-100 and TSC-101 are expected to enter clinical development for hematologic malignancies in 2021, and the company is advancing additional TCR-T cell programs for solid cancers.
The company has raised over USD 180m to date from leading strategic collaborators, including Novartis, founding investor Longwood Fund and other investors.
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
CordenPharma increases aseptic fill-finish capacity
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
Agilent launches S540MD slide scanner system in US
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA